Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Takeda Pharmaceutical Co ( (JP:4502) ) is now available.
Takeda Pharmaceutical Co. has completed the disposal of treasury shares under its Long-Term Incentive Plan for employees outside Japan, with a slight reduction in the number of shares due to partial forfeiture of rights by some allottees. This change is expected to have an immaterial impact on the company’s full-year financials, indicating a stable operational outlook despite the adjustment.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda is a leading R&D-driven biopharmaceutical company headquartered in Japan, focusing on creating transformative treatments in areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company operates in approximately 80 countries and is committed to improving patient experiences and advancing treatment options.
Average Trading Volume: 4,315,985
Technical Sentiment Signal: Buy
Current Market Cap: Yen6992.8B
See more insights into 4502 stock on TipRanks’ Stock Analysis page.